Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
- PMID: 34387172
- DOI: 10.2174/1871529X21666210812103535
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
Abstract
After the outbreak of COVID-19, many novel drugs have been introduced to improve patients' conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
Keywords: COVID-19; Remdesivir; cardiovascular; favipiravir; heart; side effect..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.Chembiochem. 2021 Mar 16;22(6):939-948. doi: 10.1002/cbic.202000595. Epub 2020 Nov 11. Chembiochem. 2021. PMID: 33031623 Free PMC article. Review.
-
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomed Pharmacother. 2022 Mar;147:112700. doi: 10.1016/j.biopha.2022.112700. Epub 2022 Feb 4. Biomed Pharmacother. 2022. PMID: 35131656 Free PMC article. Review.
-
[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].Recenti Prog Med. 2021 Mar;112(3):195-206. doi: 10.1701/3565.35458. Recenti Prog Med. 2021. PMID: 33687358 Italian.
-
Psychopharmacology of COVID-19.Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18. Psychosomatics. 2020. PMID: 32425246 Free PMC article. Review.
-
Remdesivir as a broad-spectrum antiviral drug against COVID-19.Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426. Eur Rev Med Pharmacol Sci. 2021. PMID: 33506946 Review.
Cited by
-
Transient left bundle branch block associated with favipiravir treatment for coronavirus infection.J Interv Card Electrophysiol. 2023 Sep;66(6):1321-1322. doi: 10.1007/s10840-023-01548-2. Epub 2023 Apr 26. J Interv Card Electrophysiol. 2023. PMID: 37099218 Free PMC article.
-
Favipiravir-induced bradycardia: A case report.Clin Case Rep. 2024 Jun 27;12(7):e9052. doi: 10.1002/ccr3.9052. eCollection 2024 Jul. Clin Case Rep. 2024. PMID: 38947534 Free PMC article.
-
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.Stem Cell Res Ther. 2023 Jun 26;14(1):169. doi: 10.1186/s13287-023-03402-8. Stem Cell Res Ther. 2023. PMID: 37365605 Free PMC article. Clinical Trial.
-
Rate, risk factors, and clinical outcomes of SARS-CoV-2 reinfection vs. primary infection in readmitted COVID-19 patients in Iran: a retrospective cohort study.Front Public Health. 2024 Oct 17;12:1480805. doi: 10.3389/fpubh.2024.1480805. eCollection 2024. Front Public Health. 2024. PMID: 39484354 Free PMC article.
-
Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.Heliyon. 2023 Jun;9(6):e17478. doi: 10.1016/j.heliyon.2023.e17478. Epub 2023 Jun 21. Heliyon. 2023. PMID: 37366526 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous